France-based CARMAT has been developing a total artificial heart that is set to go on sale this year in Europe. This would help patients suffering from advanced heart failure by providing them with either long-term support or to serve as a bridge to a heart transplant. It consists of an implanted prosthesis, external equipment (including batteries), and a hospital care console to track its function.
The prosthesis boasts four biological valves to facilitate blood flow, two ventricles, two micro-pumps, and inbuilt sensors to allow the heart to adapt to the patient’s needs at any given time. Last March, the company announced that a patient fitted with their artificial heart had successfully been supported for two years.
- 🏥【Realistic Three-Story Modular Design】This toy building set features a detailed three-story hospital with a modular design, allowing easy...
- 💡【Includes LED Lighting Kit】Enhance the play experience with the included LED lighting kit, bringing your hospital to life with realistic...
- 🏗️【Modular Design, Detailed Interior】Dive into the intricate layers of our modular design, facilitating easy assembly and disassembly....
The bridge-to-transplant indication that we got as part of the CE Marking represents hope for patients and a very sizable market opportunity for the Company, as at least 2,000 patients are currently on waiting lists for a heart transplant in Europe, but only a fraction of them is fortunate enough to benefit from a donor graft. In 2021, our intention is to focus our efforts on Germany and France, which account for more than half of these patients. We might also address other countries recognizing the CE marking in a more opportunistic way. I am happy to confirm that we will be ready to start selling our product as early as Q2 2021,” said Stéphane Piat, Chief Executive Officer of CARMAT.
